DiaTech Licenses Vanderbilt's Personalized Tumor Test | GenomeWeb

NEW YORK (GenomeWeb News) – DiaTech Oncology has struck a license agreement with Vanderbilt University for a microkinetic assay that can be used to determine a patient's chemotherapy treatment and dosing needs, the university said today.

The Brentwood, Tenn.-based company has licensed the MiCK test, which was developed at the Vanderbilt University School of Medicine, which will be used in a service that measures the response through apoptosis of patients' cancer cells to a number of different chemotherapeutic drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.